fashion -WSS

fashion

author：leisure time 2025-10-01 23:39:45 - browse：2

A dosage of Wegovy, a drug used for weight loss — Amanda Andrade-Rhoades/AP

U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment.

The new label indicates that Wegovy can be used to reduce the risk of major heart complications — including heart attack, stroke, or cardiovascular-related deaths — for people with overweight or obesity and existing heart disease, Novo said in a statement Friday.

The decision was based on results of a large, five-year trial that showed Wegovy cut the risk of cardiovascular problems by 20% in that population. This is the first time a weight loss treatment has been approved to also help improve heart outcomes, the FDA said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Too many hospitalized Covid

Wikipedia

WSS

ACIP vaccine advisory panel sees its vacancies filled

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Doctors on social media are being harassed and cyberbullied

Latigo launches with $135 million for Vertex

H.R. 3 is the wrong path to lower drug costs

Why don't Americans have at

Wikipedia

fashion

entertainment

In Memoriam: Notable people who died in 2023

AMAs digital advisors table RPM coding reform proposal, again

Dobbs anniversary: the lost opportunity of abortion as health care

Chris Christie meets with Zelenskyy during Ukraine trip

Heart attack and stroke risk calculators need revising

Flint parents haunted by uncertainty, fears of lead poisoning

At least 13 dead in Texas as scorching temps continue

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

After affirmative action ruling, medical educators look to 'holistic review'

Bernie Sanders gets little from pharma CEOs on drug prices

hotspot

FDA scientists endorse Pfizer/BioNTech Covid

Congress might make insulin pumps more accessible to the blind

Abbott's new heart device gets FDA advisory panel nod

Resistance to opioid

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Eli Lilly reports tirzepatide MASH success during Q4 earnings

focus

Wikipedia

explore

focus